JP2007522141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522141A5 JP2007522141A5 JP2006551821A JP2006551821A JP2007522141A5 JP 2007522141 A5 JP2007522141 A5 JP 2007522141A5 JP 2006551821 A JP2006551821 A JP 2006551821A JP 2006551821 A JP2006551821 A JP 2006551821A JP 2007522141 A5 JP2007522141 A5 JP 2007522141A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally
- substituted
- alkoxy
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 C 1 -C 10 - alkyl Chemical group 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000002829 nitrogen Chemical class 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000007864 aqueous solution Substances 0.000 claims 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims 6
- 239000006185 dispersion Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 6
- 239000000443 aerosol Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 4
- 125000002723 alicyclic group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 239000003380 propellant Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000012453 solvate Chemical group 0.000 claims 3
- 125000004434 sulfur atoms Chemical group 0.000 claims 3
- 229960004436 Budesonide Drugs 0.000 claims 2
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- GTTZQULJQRNNER-HNNXBMFYSA-N 4-hydroxy-7-[(1R)-1-hydroxy-2-[(2-methyl-1-phenylpropan-2-yl)amino]ethyl]-3H-1,3-benzothiazol-2-one Chemical compound C([C@H](O)C=1C=2SC(=O)NC=2C(O)=CC=1)NC(C)(C)CC1=CC=CC=C1 GTTZQULJQRNNER-HNNXBMFYSA-N 0.000 claims 1
- QTWVYUJFBIVOHT-SZMVWBNQSA-N 4-hydroxy-7-[(1R)-1-hydroxy-2-[[(1S,2S)-2-phenylmethoxycyclopentyl]amino]ethyl]-3H-1,3-benzothiazol-2-one Chemical compound O([C@H]1CCC[C@@H]1NC[C@H](O)C=1C=2SC(=O)NC=2C(O)=CC=1)CC1=CC=CC=C1 QTWVYUJFBIVOHT-SZMVWBNQSA-N 0.000 claims 1
- ONNGKMAEIWXVBI-UHFFFAOYSA-N 4-hydroxy-7-[1-hydroxy-2-[2-[4-(4-phenylbutoxy)phenyl]ethylamino]ethyl]-3H-1,3-benzothiazol-2-one Chemical compound C=1C=C(O)C=2NC(=O)SC=2C=1C(O)CNCCC(C=C1)=CC=C1OCCCCC1=CC=CC=C1 ONNGKMAEIWXVBI-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 229940092703 Beclomethasone Dipropionate Drugs 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 claims 1
- 229940071648 Metered Dose Inhaler Drugs 0.000 claims 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N Rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims 1
- 229950004432 Rofleponide Drugs 0.000 claims 1
- 229960002117 Triamcinolone Acetonide Drugs 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
- 125000005035 acylthio group Chemical group 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- ZEXCGJJNMGJWDF-FERBBOLQSA-N formic acid;4-hydroxy-7-[(1R)-1-hydroxy-2-[2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethylamino]ethyl]-3H-1,3-benzothiazol-2-one Chemical compound OC=O.C1([C@H](CNCCC=2C=C3CCCCC3=CC=2)O)=CC=C(O)C2=C1SC(=O)N2 ZEXCGJJNMGJWDF-FERBBOLQSA-N 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 125000004468 heterocyclylthio group Chemical group 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 125000000962 organic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0402797.5A GB0402797D0 (en) | 2004-02-09 | 2004-02-09 | Organic compounds |
PCT/EP2005/001241 WO2005074924A1 (fr) | 2004-02-09 | 2005-02-08 | Combinaison d'agonistes de l'adrenorecepteur beta2 de la benzothiazol-2-one et de corticosteroides dans le traitement des maladies respiratoires |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007522141A JP2007522141A (ja) | 2007-08-09 |
JP2007522141A5 true JP2007522141A5 (fr) | 2008-03-21 |
Family
ID=31985893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006551821A Pending JP2007522141A (ja) | 2004-02-09 | 2005-02-08 | 呼吸器疾患の処置のためのベンゾチアゾール−2−オンベータ2アドレナリン受容体アゴニストとコルチコステロイドの組合せ剤 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1715860A1 (fr) |
JP (1) | JP2007522141A (fr) |
KR (1) | KR20060127974A (fr) |
CN (1) | CN1917875A (fr) |
AR (1) | AR047962A1 (fr) |
AU (1) | AU2005210140A1 (fr) |
BR (1) | BRPI0507544A (fr) |
CA (1) | CA2552938A1 (fr) |
GB (1) | GB0402797D0 (fr) |
PE (1) | PE20050692A1 (fr) |
RU (1) | RU2006132195A (fr) |
TW (1) | TW200536533A (fr) |
WO (1) | WO2005074924A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
JP5257073B2 (ja) * | 2005-11-10 | 2013-08-07 | ボーダー、ニコラス・エス | ソフト型抗コリン作動性エステル |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200745067A (en) * | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
EP2011534A1 (fr) * | 2007-07-03 | 2009-01-07 | CHIESI FARMACEUTICI S.p.A. | Actionneur d'inhalateur à dosage mesuré |
ES2399945T3 (es) | 2007-11-30 | 2013-04-04 | Pfizer Limited | Agonistas novedosos de los receptores de glucocorticoides |
CA2709071C (fr) | 2007-12-14 | 2016-11-15 | Labogroup S.A.S. | Administration de produits alimentaires sous forme d'aerosols |
PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
CN102124003A (zh) | 2008-06-18 | 2011-07-13 | 阿斯利康(瑞典)有限公司 | 作为治疗呼吸系统疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物 |
WO2011061527A1 (fr) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
KR20220119529A (ko) | 2016-06-02 | 2022-08-29 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
ES2877659T3 (es) | 2017-12-01 | 2021-11-17 | Abbvie Inc | Agonista del receptor de glucocorticoides y sus inmunoconjugados |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009018A1 (fr) * | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2 |
AR040962A1 (es) * | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
-
2004
- 2004-02-09 GB GBGB0402797.5A patent/GB0402797D0/en not_active Ceased
-
2005
- 2005-02-05 TW TW094103838A patent/TW200536533A/zh unknown
- 2005-02-08 CN CNA2005800044314A patent/CN1917875A/zh active Pending
- 2005-02-08 EP EP05707254A patent/EP1715860A1/fr not_active Withdrawn
- 2005-02-08 KR KR1020067016003A patent/KR20060127974A/ko not_active Application Discontinuation
- 2005-02-08 RU RU2006132195/15A patent/RU2006132195A/ru not_active Application Discontinuation
- 2005-02-08 CA CA002552938A patent/CA2552938A1/fr not_active Abandoned
- 2005-02-08 BR BRPI0507544-0A patent/BRPI0507544A/pt not_active IP Right Cessation
- 2005-02-08 WO PCT/EP2005/001241 patent/WO2005074924A1/fr active Application Filing
- 2005-02-08 AU AU2005210140A patent/AU2005210140A1/en not_active Abandoned
- 2005-02-08 JP JP2006551821A patent/JP2007522141A/ja active Pending
- 2005-02-09 AR ARP050100452A patent/AR047962A1/es not_active Application Discontinuation
- 2005-02-09 PE PE2005000154A patent/PE20050692A1/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007522141A5 (fr) | ||
RU2006132195A (ru) | Комбинация агонистов бета-2 адренорецептора, бензотиазол-2-онов и кортикостероидов, предназначенная для лечения респираторных заболеваний | |
JP2004514739A5 (fr) | ||
CA2427282A1 (fr) | Composes organiques ou melanges pour le traitements des maladies des voies respiratoires | |
JP2018199684A5 (fr) | ||
JP2010215637A (ja) | β2−アゴニストの溶液を含有する加圧式定量用量吸入器 | |
CN104994854A (zh) | 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法 | |
EP2621588A2 (fr) | Procédés et compositions pour le traitement de maladie en utilisant l'inhalation | |
RU2008124833A (ru) | Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций | |
UA82217C2 (uk) | Медикамент, що містить бета2-агоніст у комбінації з будезонідом, для лікування запальних або обструктивних хвороб дихальних шляхів | |
JP2017528479A (ja) | Rpl554を含む液体吸入製剤 | |
WO2011136754A1 (fr) | Médicament mis au point pour le traitement de maladies respiratoires | |
JP2019528316A5 (fr) | ||
JP2014516062A (ja) | ウメクリジニウム及びコルチコステロイドを含む組合せ | |
JP2020023537A (ja) | Copdの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ | |
JP2015519356A5 (fr) | ||
PT2398473E (pt) | 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1- hidroxietil)-8-hidroxiquinolin-2(1h)-ona para o tratamento da função pulmonar | |
WO2011136753A1 (fr) | Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires | |
JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
TWI436761B (zh) | 使用噻唑衍生物之方法 | |
JP2011500731A5 (fr) | ||
RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
ES2917879T3 (es) | Nuevo uso de aclidinio | |
JP2004500434A (ja) | サルメテロールとブデソニドを含む組合せ医薬 |